One pill to rule them all? triple diabetes combo under study

NCT ID NCT06862739

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a single pill containing three diabetes drugs (empagliflozin, linagliptin, and metformin) in 800 adults with type 2 diabetes. The goal is to see if the triple combination improves blood sugar control, weight, quality of life, and treatment satisfaction compared to current options. Participants must have an HbA1c of 8% or higher and already be on at least two diabetes medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
empagliflozin, linagliptin, and metformin combined in one pill
What this could lead to
If successful, this single-pill combination could simplify diabetes management, improve blood sugar control, and boost patient satisfaction.
What could go wrong
This is a phase 4 study, so the drugs are already approved, but the triple combination may not work better than existing options and could increase side effects like hypoglycemia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Aap ka Clinic

    RECRUITING

    Lahore, Punjab Province, Pakistan

  • Faisalabad clinics

    RECRUITING

    Faisalabad, Punjab Province, Pakistan

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.